UCB PHARMA SA

UCB PHARMA SA logo
🇧🇪Belgium
Ownership
Public, Subsidiary
Established
1928-01-01
Employees
9K
Market Cap
$34.9B
Website
https://www.ucb-iberia.com/home
Clinical Trials
Related News

Long-term Open-label Trial in Idiopathic Restless Legs Syndrome (RLS)

Phase 2
Completed
Conditions
Restless Legs Syndrome
Interventions
Drug: Rotigotine
First Posted Date
2007-07-09
Last Posted Date
2014-10-02
Lead Sponsor
UCB Pharma
Target Recruit Count
295
Registration Number
NCT00498186

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Phase 3
Completed
Conditions
Epilepsy
Interventions
Other: Placebo
Drug: Brivaracetam
First Posted Date
2007-06-22
Last Posted Date
2022-07-21
Lead Sponsor
UCB Pharma SA
Target Recruit Count
399
Registration Number
NCT00490035
Locations
🇫🇷

52, Montpellier Cedex, France

🇩🇪

71, Ulm, Germany

🇭🇺

94, Budapest, Hungary

and more 73 locations

Trial to Assess Efficacy and Safety of Lacosamide in Subjects With Osteoarthritis of the Knee

Phase 2
Terminated
Conditions
Osteoarthritis
Interventions
Other: Placebo
Drug: lacosamide
First Posted Date
2007-06-13
Last Posted Date
2017-08-28
Lead Sponsor
UCB Pharma
Target Recruit Count
194
Registration Number
NCT00485472

Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Phase 2
Terminated
Conditions
Multiple Sclerosis
Interventions
Drug: CDP323
Drug: placebo
First Posted Date
2007-06-11
Last Posted Date
2011-09-12
Lead Sponsor
UCB Pharma
Target Recruit Count
232
Registration Number
NCT00484536

Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine

Phase 3
Completed
Conditions
Parkinson's Disease
Interventions
Drug: Rotigotine
Other: Placebo
First Posted Date
2007-05-16
Last Posted Date
2015-06-22
Lead Sponsor
UCB Pharma
Target Recruit Count
287
Registration Number
NCT00474058

The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults.

Phase 2
Completed
Conditions
Fibromyalgia Syndrome
Interventions
Other: Placebo
Drug: Rotigotine
First Posted Date
2007-04-24
Last Posted Date
2015-06-22
Lead Sponsor
UCB Pharma
Target Recruit Count
230
Registration Number
NCT00464737

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

First Posted Date
2007-04-23
Last Posted Date
2022-07-21
Lead Sponsor
UCB Pharma
Target Recruit Count
400
Registration Number
NCT00464269

Evaluation of Treatment Satisfaction in Children With an Allergy and Who Received an Antihistamine

Completed
Conditions
Allergies
First Posted Date
2007-03-29
Last Posted Date
2013-12-16
Lead Sponsor
UCB Pharma
Target Recruit Count
4581
Registration Number
NCT00453583
Locations
🇺🇸

UCB Pharma, Smyrna, Georgia, United States

A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis

Phase 2
Completed
Conditions
Migraine
Interventions
Other: Placebo
Drug: Lacosamide
First Posted Date
2007-02-27
Last Posted Date
2018-07-17
Lead Sponsor
UCB Pharma
Target Recruit Count
218
Registration Number
NCT00440518

An Open-Label Interaction Study to Look at the Effects of Brivaracetam on Phenytoin When Taken Together in 15 Adult Patients With Epilepsy.

Phase 1
Completed
Conditions
Epilepsy
First Posted Date
2007-01-25
Last Posted Date
2008-03-10
Lead Sponsor
UCB Pharma
Target Recruit Count
15
Registration Number
NCT00426673
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy